Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.77 |
| ▸ | MET | P08581 | 3/20 | 0.77 |
| ▸ | INSR | P06213 | 9/20 | 0.61 |
| ▸ | IGF1R | P08069 | 9/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.57 |
| ▸ | AURKA | O14965 | 2/20 | 0.57 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.57 |
| ▸ | JAK2 | O60674 | 2/20 | 0.57 |
| ▸ | STK10 | O94804 | 2/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.57 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.57 |
| ▸ | ABL1 | P00519 | 2/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.57 |
| ▸ | LCK | P06239 | 2/20 | 0.57 |
| ▸ | FYN | P06241 | 2/20 | 0.57 |
| ▸ | FES | P07332 | 2/20 | 0.57 |
| ▸ | CSF1R | P07333 | 2/20 | 0.57 |
| ▸ | YES1 | P07947 | 2/20 | 0.57 |
| ▸ | LYN | P07948 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25308149 | 0.98 | EGFR (0.80) | EGFRMETINSRIGF1RALK | |
| SCHEMBL25307926 | 0.95 | EGFR (0.68) | EGFRMETINSRIGF1RALK | |
| SCHEMBL26496137 | 0.94 | EGFR (0.80) | EGFRMETINSRIGF1RALK | |
| SCHEMBL25258208 | 0.94 | EGFR (0.79) | EGFRMETINSRIGF1RALK | |
| SCHEMBL25305824 | 0.92 | EGFR (0.69) | EGFRMETINSRIGF1RALK | |
| SCHEMBL25300304 | 0.90 | EGFR (0.68) | EGFRMETINSRIGF1RALK | |
| SCHEMBL25305317 | 0.90 | EGFR (0.71) | EGFRMETINSRIGF1RALK | |
| SCHEMBL25306866 | 0.89 | EGFR (0.69) | EGFRMETINSRIGF1RALK | |
| SCHEMBL25307921 | 0.89 | EGFR (0.71) | EGFRMETINSRIGF1RALK | |
| SCHEMBL26495848 | 0.89 | EGFR (0.73) | EGFRMETINSRIGF1RALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H BIOTECH INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H BIOTECH INC. (KR) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | EGFR, KRAS, ERBB2 | EGFR 1/4885MET 14/4885INSR 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.